Differences in expression rather than methylation at placenta-specific imprinted loci is associated with intrauterine growth restriction.


Journal

Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977

Informations de publication

Date de publication:
26 02 2019
Historique:
received: 23 11 2018
accepted: 08 02 2019
entrez: 28 2 2019
pubmed: 28 2 2019
medline: 21 8 2019
Statut: epublish

Résumé

Genome-wide studies have begun to link subtle variations in both allelic DNA methylation and parent-of-origin genetic effects with early development. Numerous reports have highlighted that the placenta plays a critical role in coordinating fetal growth, with many key functions regulated by genomic imprinting. With the recent description of wide-spread polymorphic placenta-specific imprinting, the molecular mechanisms leading to this curious polymorphic epigenetic phenomenon is unknown, as is their involvement in pregnancies complications. Profiling of 35 ubiquitous and 112 placenta-specific imprinted differentially methylated regions (DMRs) using high-density methylation arrays and pyrosequencing revealed isolated aberrant methylation at ubiquitous DMRs as well as abundant hypomethylation at placenta-specific DMRs. Analysis of the underlying chromatin state revealed that the polymorphic nature is not only evident at the level of allelic methylation, but DMRs can also adopt an unusual epigenetic signature where the underlying histones are biallelically enrichment of H3K4 methylation, a modification normally mutually exclusive with DNA methylation. Quantitative expression analysis in placenta identified two genes, GPR1-AS1 and ZDBF2, that were differentially expressed between IUGRs and control samples after adjusting for clinical factors, revealing coordinated deregulation at the chromosome 2q33 imprinted locus. DNA methylation is less stable at placenta-specific imprinted DMRs compared to ubiquitous DMRs and contributes to privileged state of the placenta epigenome. IUGR-associated expression differences were identified for several imprinted transcripts independent of allelic methylation. Further work is required to determine if these differences are the cause IUGR or reflect unique adaption by the placenta to developmental stresses.

Sections du résumé

BACKGROUND
Genome-wide studies have begun to link subtle variations in both allelic DNA methylation and parent-of-origin genetic effects with early development. Numerous reports have highlighted that the placenta plays a critical role in coordinating fetal growth, with many key functions regulated by genomic imprinting. With the recent description of wide-spread polymorphic placenta-specific imprinting, the molecular mechanisms leading to this curious polymorphic epigenetic phenomenon is unknown, as is their involvement in pregnancies complications.
RESULTS
Profiling of 35 ubiquitous and 112 placenta-specific imprinted differentially methylated regions (DMRs) using high-density methylation arrays and pyrosequencing revealed isolated aberrant methylation at ubiquitous DMRs as well as abundant hypomethylation at placenta-specific DMRs. Analysis of the underlying chromatin state revealed that the polymorphic nature is not only evident at the level of allelic methylation, but DMRs can also adopt an unusual epigenetic signature where the underlying histones are biallelically enrichment of H3K4 methylation, a modification normally mutually exclusive with DNA methylation. Quantitative expression analysis in placenta identified two genes, GPR1-AS1 and ZDBF2, that were differentially expressed between IUGRs and control samples after adjusting for clinical factors, revealing coordinated deregulation at the chromosome 2q33 imprinted locus.
CONCLUSIONS
DNA methylation is less stable at placenta-specific imprinted DMRs compared to ubiquitous DMRs and contributes to privileged state of the placenta epigenome. IUGR-associated expression differences were identified for several imprinted transcripts independent of allelic methylation. Further work is required to determine if these differences are the cause IUGR or reflect unique adaption by the placenta to developmental stresses.

Identifiants

pubmed: 30808399
doi: 10.1186/s13148-019-0630-4
pii: 10.1186/s13148-019-0630-4
pmc: PMC6390544
doi:

Substances chimiques

DNA-Binding Proteins 0
Histones 0
ZDBF2 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

35

Références

J Med Genet. 2015 Jul;52(7):446-53
pubmed: 25951829
Semin Perinatol. 2008 Aug;32(4):274-80
pubmed: 18652928
Genome Res. 2014 Apr;24(4):554-69
pubmed: 24402520
Biol Reprod. 2003 Jul;69(1):1-7
pubmed: 12620937
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8292-7
pubmed: 12829789
Public Health Nutr. 2016 Oct;19(14):2562-71
pubmed: 27056033
Am J Clin Nutr. 2011 Dec;94(6 Suppl):1943S-1952S
pubmed: 22049164
Biol Reprod. 2013 Sep 05;89(3):50
pubmed: 23884645
Nature. 2016 Oct 13;538(7624):248-252
pubmed: 27680694
Am J Hum Genet. 2016 Nov 3;99(5):1045-1058
pubmed: 27843122
Nat Genet. 2017 Jan;49(1):110-118
pubmed: 27841881
Placenta. 2006 Apr;27 Suppl A:S98-102
pubmed: 16503350
PLoS Genet. 2016 Nov 11;12(11):e1006427
pubmed: 27835649
Epigenetics. 2013 Jun;8(6):635-45
pubmed: 23764515
J Mol Med (Berl). 2008 Oct;86(10):1171-81
pubmed: 18607558
Hum Mol Genet. 2014 Dec 1;23(23):6275-85
pubmed: 24993786
PLoS One. 2014 Jun 25;9(6):e100148
pubmed: 24963923
PLoS Genet. 2015 Nov 06;11(11):e1005644
pubmed: 26544189
J Assist Reprod Genet. 2014 Oct;31(10):1361-8
pubmed: 24986528
Hum Reprod. 2018 Feb 1;33(2):331-340
pubmed: 29237055
Environ Res. 2012 Aug;117:100-11
pubmed: 22726801
Reprod Sci. 2011 Nov;18(11):1111-7
pubmed: 21693779
Philos Trans R Soc Lond B Biol Sci. 2015 Mar 5;370(1663):20140074
pubmed: 25602077
Environ Health Perspect. 2013 Nov-Dec;121(11-12):1365-71
pubmed: 24021707
Placenta. 2015 Aug;36(8):790-5
pubmed: 26162698
Nat Rev Endocrinol. 2017 Feb;13(2):105-124
pubmed: 27585961
Circulation. 2017 Nov 7;136(19):1824-1839
pubmed: 28904069
Nat Genet. 2005 Sep;37(9):1003-7
pubmed: 16086014
Acta Paediatr Suppl. 2004 Dec;93(446):26-33
pubmed: 15702667
Clin Perinatol. 2004 Dec;31(4):743-64, vi
pubmed: 15519426
Genome Res. 2016 Jun;26(6):756-67
pubmed: 26769960
Hypertens Pregnancy. 2016 Nov;35(4):573-582
pubmed: 27624400
Placenta. 2010 Mar;31(3):197-202
pubmed: 20060582
Genes Dev. 2014 Mar 1;28(5):463-78
pubmed: 24589776
Environ Epigenet. 2016 Mar;2(1):
pubmed: 27308065
Placenta. 2006 Jun-Jul;27(6-7):540-9
pubmed: 16125225
Epigenetics. 2015;10(9):842-9
pubmed: 26186239
Front Genet. 2016 Apr 26;7:62
pubmed: 27200075
Am J Hum Genet. 2016 Sep 1;99(3):555-566
pubmed: 27569549
Cancer Causes Control. 2012 Apr;23(4):635-45
pubmed: 22392079
Int J Biochem Cell Biol. 2015 Oct;67:128-38
pubmed: 25966912
Epigenetics. 2009 May 16;4(4):235-40
pubmed: 19483473
Biol Reprod. 2014 Feb 06;90(2):22
pubmed: 24337315
Annu Rev Genomics Hum Genet. 2009;10:241-62
pubmed: 19630559
Dis Model Mech. 2011 Nov;4(6):814-21
pubmed: 21729874

Auteurs

Ana Monteagudo-Sánchez (A)

Imprinting and Cancer Group, Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute - IDIBELL, Av. Gran Via de L'Hospotalet 199-203, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.

Marta Sánchez-Delgado (M)

Imprinting and Cancer Group, Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute - IDIBELL, Av. Gran Via de L'Hospotalet 199-203, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.

Jose Ramon Hernandez Mora (JRH)

Imprinting and Cancer Group, Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute - IDIBELL, Av. Gran Via de L'Hospotalet 199-203, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.

Nuria Tubío Santamaría (NT)

Imprinting and Cancer Group, Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute - IDIBELL, Av. Gran Via de L'Hospotalet 199-203, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Leibniz Institute on Aging, Jena, Germany.

Eduard Gratacós (E)

Fetal I+D Fetal Medicine Research Center, BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Déu, Barcelona, Spain.

Manel Esteller (M)

Cancer Epigenetics group, Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute - IDIBELL, Gran via, L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain.
Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.

Miguel López de Heredia (ML)

Human Molecular Genetics group, Genes, disease and Therapy Program, Bellvitge Biomedical Research Institute - IDIBELL, Av. Gran Via de L'Hospitalet 199-203, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.

Virgina Nunes (V)

Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain.
Human Molecular Genetics group, Genes, disease and Therapy Program, Bellvitge Biomedical Research Institute - IDIBELL, Av. Gran Via de L'Hospitalet 199-203, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigaciòn Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.

Cecile Choux (C)

Université Bourgogne Franche-Comté - INSERM UMR1231, F-21000, Dijon, France.

Patricia Fauque (P)

Université Bourgogne Franche-Comté - INSERM UMR1231, F-21000, Dijon, France.

Guiomar Perez de Nanclares (GP)

(Epi) Genetics Laboratory, BioAraba National Health Institute, Hospital Universitario Araba-Txagorritxu, Vitoria-Gasteiz, Alava, Spain.

Lauren Anton (L)

Maternal and Child Health Research Program, Department of Obstetrics and Gynecology, Center for Research on Reproduction and Women's Health, University of Pennsylvania, Philadelphia, USA.

Michal A Elovitz (MA)

Maternal and Child Health Research Program, Department of Obstetrics and Gynecology, Center for Research on Reproduction and Women's Health, University of Pennsylvania, Philadelphia, USA.

Isabel Iglesias-Platas (I)

GReN (Grup de Reçerca en Neonatologia), BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine, Institut de Reçerca Sant Joan de Déu, Barcelona, Spain.

David Monk (D)

Imprinting and Cancer Group, Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute - IDIBELL, Av. Gran Via de L'Hospotalet 199-203, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. dmonk@idibell.cat.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH